SARS-CoV-2 variants from mink evade inhibition by antibodies
Por um escritor misterioso
Descrição
It has been known for about a year that minks can become infected with SARS-CoV-2. The virus had been transmitted from humans to farmed mink and mutated in infected animals. Mutations were acquired in the spike protein, which is crucial for the entry of the virus into host cells and represents the central point of attack for antibodies. These SARS-CoV-2 variants from mink were transmitted back to humans, raising concerns that minks could be a continuing source of infection of humans with SARS-CoV-2 variants with altered biological properties. Researchers at the German Primate Center (DPZ) - Leibniz Institute for Primate Research in Göttingen, Germany, have now shown that an antibody used for COVID-19 therapy is unable to effectively inhibit SARS-CoV-2 harboring a spike mutation acquired in minks. In addition, the mutation reduced the inhibition of the virus by antibodies produced in SARS-CoV-2 infected humans. These results show that SARS-CoV-2 can acquire mutations in minks that may reduce control of the virus by the human immune system. The study and findings have been published in Cell Reports.
SARS-CoV-2 Spike Protein (S1) (E5S3V) Rabbit mAb
Towards the development of a SARS-CoV-2 variant risk assessment tool: expert consultation on the assessment of scientific evidence on emerging variants - The Lancet Microbe
SARS-CoV-2 variants: A double-edged sword? - Manasi P Jogalekar, Anurag Veerabathini, Prakash Gangadaran, 2021
Microorganisms, Free Full-Text
Two Years into the COVID-19 Pandemic: Lessons Learned
SARS-CoV-2 evolution in animals suggests mechanisms for rapid variant selection
Mink-derived SARS-CoV-2 mutations reduce antibody effectiveness
Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes
SARS-CoV-2 spike protein: pathogenesis, vaccines, and potential therapies
Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity
Evasion of vaccine-induced humoral immunity by emerging sub-variants of SARS -CoV-2
Neutralization of SARS‐CoV‐2 by highly potent, hyperthermostable, and mutation‐tolerant nanobodies
Mutational analysis of SARS-CoV-2 variants of concern reveals key tradeoffs between receptor affinity and antibody escape
de
por adulto (o preço varia de acordo com o tamanho do grupo)
.jpg)
